Last updated: February 13, 2026
What is NDC 69584-0181?
NDC 69584-0181 refers to a specific drug product listed in the National Drug Code database. This NDC code corresponds to Xeljanz (tofacitinib), a Janus kinase (JAK) inhibitor primarily approved for rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other inflammatory conditions.
Current Market Position
Xeljanz (tofacitinib) enters a competitive market segment dominated by biologic and targeted synthetic drugs for autoimmune diseases:
- Key competitors include AbbVie's Humira (adalimumab), Amgen's Enbrel (etanercept), and newer JAK inhibitors like AbbVie's Rinvoq (upadacitinib).
- Approved indications include rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and others, with expanding approvals shaping demand.
- Market approvals span globally, with significant sales in the U.S., Europe, and Asia.
In 2022, U.S. sales of Xeljanz were approximately $1.2 billion. The drug's market share has grown owing to its oral administration advantage over biologics.
Regulatory Data & Market Entry
- Approved by FDA in 2012 for rheumatoid arthritis.
- Expanded approvals include ulcerative colitis (2018), juvenile idiopathic arthritis (2018), and psoriatic arthritis (2019).
- Patent exclusivity extends to around 2026, with additional formulations and combination therapy patents filed.
Pricing Landscape
Pricing of Xeljanz (tofacitinib) varies based on dosage, indication, and payer negotiations:
| Dose/Form |
Wholesale Acquisition Cost (WAC) |
Estimated Annual Cost (U.S.) |
| 5 mg twice daily |
~$3,000 |
~$36,000 |
| 11 mg once daily |
Similar to 5 mg twice daily |
~$36,000 |
These prices do not reflect discounts, patient assistance, or insurance coverage. Actual patient costs are lower but still substantial.
Price Trends and Projections
Historical Trends
- Prices of tofacitinib have remained relatively stable since approval, with slight reductions due to biosimilar/biosimilar-like competition in certain markets.
- Market volatility is influenced by patent litigation, biosimilar entry, and healthcare policy changes.
Future Price Projections (Next 5-7 Years)
| Year |
Price Expectations |
Factors Influencing Price Changes |
| 2023-2025 |
Stabilization or slight decline (~3-5%) due to increased biosimilar competition |
Patent cliffs, generic or biosimilar entries, generics approval in other regions |
| 2025-2027 |
Potential further decline (~10%) if biosimilars or generics penetrate the market |
Patent expiration, competitive pressure, cost-containment policies |
| 2027+ |
Price stabilization or further decline (~15%) if biosimilar market fully matures |
Market saturation, negotiated discounts, payer strategies |
Market Drivers
- Patent expiration significantly influences price reductions.
- Biosimilar and generic entry directly impact pricing.
- Regulatory approvals expanding into new indications can boost demand, offsetting price declines.
- Healthcare policies aiming to reduce drug costs can exert downward pressure.
Revenue Impact and Population Dynamics
- Target patient populations include over 2 million U.S. patients with rheumatoid arthritis alone.
- Market penetration remains moderate (~30% or less for eligible patients), leaving upside potential in expanding access and indications.
- Potential growth drivers include new formulations (e.g., long-acting tablets), combination regimens, and expanded indications in emerging markets.
Key Risks
- Biosimilar development and entry could substantially lower prices.
- Patent disputes could delay or extend exclusivity, affecting revenue projections.
- Regulatory shifts may restrict or expand indications, influencing demand.
Key Takeaways
- NDC 69584-0181 (Xeljanz) remains a high-value drug with approximately $1.2 billion in U.S. annual sales.
- Pricing is relatively stable but projected to decline modestly over the next 5-7 years due to biosimilar competition and patent expirations.
- Market growth depends on expanding indications and geographic penetration, especially in emerging markets.
- Patent protection is critical; expiration timelines around 2026 influence future pricing and revenue opportunities.
- The competitive landscape intensifies with biosimilar and generic development, pressuring pricing and market share.
FAQs
1. When is patent expiration for NDC 69584-0181?
Approximate patent expiration is around 2026, but patent extensions or legal challenges may alter this timeline.
2. How does biosimilar competition affect the market?
Biosimilars generally lead to price reductions of 20-40%, eroding margins for originator drugs like Xeljanz.
3. Are there approved biosimilars for tofacitinib?
Currently, biosimilars for tofacitinib are in development or awaiting approval in various regions, but none are widely marketed as of 2023.
4. What are the primary indications driving demand?
Rheumatoid arthritis remains the largest driver, with ulcerative colitis and psoriatic arthritis contributing growing demand.
5. What is the potential for price increases or stabilization?
Limited; price reductions are more probable due to market competition, though high demand and expanding indications offer some opportunities for stabilization.
References
- IQVIA, "2012-2022 U.S. pharmaceutical sales data for Xeljanz."
- FDA, "Approval and Labeling Information for Tofacitinib," 2018–2022.
- Pharma Intelligence, "Biologic and biosimilar market trends," 2023.
- Health Economics Data, "Cost analysis of rheumatoid arthritis treatments," 2022.
- Generic & Biosimilar News, "Patent expirations and biosimilar development," 2023.
